This is a working overview of Freeze-thaw cycling, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentapeptide | Chain of five amino acid residues |
| Molecular mass | Approximately 712 Da | Consistent with a five-residue chain |
| Receptor target | GHS-R1a | Growth hormone secretagogue receptor |
| Primary action | Growth hormone release | Pituitary somatotroph stimulation |
| Research origin | Developed in the 1990s | Small-peptide secretagogue program |
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
杂质谱一般包含缺失序列片段、差向异构体、氧化产物以及残留溶剂或反离子，其中组氨酸与芳香残基的氧化常被重点关注。反相色谱中这类杂质往往紧邻主峰洗脱，因此方法需要足够的分离度并经过系统适用性验证。纯度百分比的解读依赖于检测波长与梯度条件，不同实验室公布的数字不宜直接横向比较。参考标准品有助于跨批次对照，但其自身赋值同样需要可追溯来源。
冻干状态下的肽通常比溶液状态更稳定，常规做法是维持 -20 °C 或更低温度、保持干燥并避开强光。复溶后的降解主要来自水解、氧化与脱酰胺，速率受 pH、缓冲液种类、离子强度与温度共同影响，碱性条件一般会加快这些反应。反复冻融会造成聚集与容器吸附损失，分装保存能降低该风险。容器材质与金属离子也可能参与氧化过程，需与操作条件一并考虑。
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
Long-term storage of the dry powder is typically at minus twenty degrees Celsius or lower, protected from light and moisture. Solutions are commonly kept frozen and thawed only once, because repeated freeze-thaw cycles can promote aggregation and loss of measurable peptide content. Buffers near neutral pH are preferred over strongly acidic or strongly basic conditions. Shipping at ambient temperature is acceptable for short periods when the powder remains sealed and desiccated.
Food and Drug Administration (FDA) has issued a black box warning for suicidal behavior/ideation. Similar warnings have been issued in Australia. Unlike stimulant medications, atomoxetine does not have misuse liability or the potential to cause withdrawal effects upon abrupt discontinuation. Atomoxetine has been found to directly inhibit hERG potassium currents with an IC50Tooltip half-maximal inhibitory concentration of 6,300 nM, which has the potential to cause arrhythmia. No substantial QTc interval changes were observed in a clinical study of atomoxetine in CYP2D6 poor metabolizers. However, small changes could not be ruled out, and there was a slight but significant increase in QTc interval with higher atomoxetine concentrations. QT prolongation has been reported with atomoxetine at therapeutic doses and in overdose; it is suggested that atomoxetine not be used with other medications that may prolong the QT interval, concomitantly with CYP2D6 inhibitors, and caution to be used in poor metabolizers. Unlike α2-adrenergic receptor agonists such as guanfacine and clonidine, atomoxetine's use can be abruptly stopped without significant withdrawal symptoms being observed.
== Interactions == Ertapenem can reduce the concentrations of valproic acid, an epilepsy medication, by 70% and perhaps up to 95% within 24 hours; this can result in inadequate control of seizures. The effect is described for other carbapenem antibiotics as well, but seems to be most pronounced for ertapenem and meropenem. This is likely caused by several mechanisms: carbapenems inhibit transport of valproic acid from the gut into the body; they may increase metabolization of valproic acid to its glucuronide; they may reduce enterohepatic circulation and recycling of valproic acid glucuronide by acting against gut bacteria; and they may block transporter proteins that pump valproic acid out of red blood cells into the blood plasma. The effect is also seen in reverse: in cases where ertapenem has been withdrawn blood concentrations of valproate have been reported to rise. Drug interactions via the cytochrome P450 enzyme system or the P-glycoprotein transporter are considered unlikely, as these proteins are not involved in the metabolism of ertapenem.
The introduction of nucleophilic catalyst can significantly enhance reaction rate (shown in Figure 7). For example, using aniline as a nucleophilic catalyst, a less populated protonated carbonyl becomes a highly populated protonated Schiff base. In other words, it generates a high concentration of reactive electrophile. The oxime ligation can then occur readily, and it has been reported that the rate increased up to 400 times under mild acidic condition. The key of this catalyst is that it can generate a reactive electrophile without competing with desired product.
A study by Aphekom comparing ten large French cities showed that Le Havre is the least polluted urban commune of France. Le Havre is also the third best city in France with more than 100,000 inhabitants for air quality. A Carbon accounting showed in 2009 that the municipality ejected some 32,500 tonnes of CO2 per year. In 2011 the average annual emissions of sulfur dioxide by industry was between three micrograms per cubic metre in the centre of Le Havre to twelve micrograms per cubic metre in the district of Caucriauville. The municipality has set a target to reduce emissions of CO2 by 3% per year. To achieve this solar panels have been installed on several municipal buildings (city hall, hanging gardens). Since 2008, Le Havre has been part of the network of Energy Cities and, in this context, it applies the steps of Agenda 21 and an Environmental Approach to Urban Planning. The city has received many awards of eco-labels several times (Energy of the Future label in 2009–2011, sustainable Earth label in 2009). Since 1998, Le Havre's beach has received the Blue Flag yearly thanks to its range of facilities, which extend over 30,000 m2. Le Havre has kept extensive green areas (750 hectares or 41 m2 per inhabitant), the two largest areas are the Montgeon Forest and Rouelles Park which are both located in the upper town. The gardens of the Priory of Graville and the hanging gardens offer views of the lower city. In the city centre, Saint-Roch Square and the City Hall Gardens provide the people with urban recreation areas.
=== Basal regulation === Under normal, unstressed conditions, p53 is maintained at low levels through continuous degradation mediated by the E3 ubiquitin ligase MDM2 (HDM2 in humans). MDM2 binds p53, exports it from the nucleus, and targets it for proteasomal degradation. Notably, p53 transcriptionally activates MDM2, establishing a classic negative feedback loop. This feedback loop gives rise to damped oscillations in p53 levels, as demonstrated both experimentally and in mathematical models. These oscillations may determine cell fate decisions between survival and apoptosis.
Sources: en.wikipedia.org
=== Absorption and distribution === As calciseptine is injected by the snake into its prey along with the rest of its venom, it does not have to pass the protective barrier of the skin and is injected directly into the tissues and/or bloodstream of the prey. No research has been conducted on the toxicokinetics of calciseptine specifically, but general research about snake toxin dynamics is available. Although the toxic peptides are generally small (about 60 amino acids), their size is sufficient to prevent them from crossing epithelial layers like the blood–brain barrier. Bioavailability measurements have been conducted for several snake venoms. For example, cobra venom has been found to have a bioavailability of 41.7% when injected intramuscular, and for other venoms this may even be less than 10%. These values are quite low compared to those of most therapeutic drugs, which usually have a bioavailability of nearly 100% after intramuscular injection. In general, toxic peptides of 10-40 amino acids have been found to have a relatively poor bioavailability due to their size and hydrophilicity. Thus, calciseptine, containing 60 amino acids, is expected to have a low bioavailability as well.
The Ukrainian Ground Forces announced that Andrii Kovalchuk, the head of its Operational Command South, had been appointed as head of the Odesa Military Academy, while Serhii Litvinov, the head of its Operational Command West, had been appointed as deputy head of the National Defence University of Ukraine. They were replaced in their previous positions by Major General Hennadii Shapovalov and Brigade General Volodymyr Shvediuk, respectively.
An alternative approach to the identification and quantification of patient samples is through the use of mass spectrometry. This approach offers excellent precision and sensitivity in the identification, characterization and quantification of metabolites in multiple patient sample types, such as blood and urine. The mass spectrometry (MS) approach is typically coupled to gas chromatography (GC), in GC-MS or liquid chromatography (LC), in LC-MS, which aid in initially separating out the metabolite components within complex sample mixtures, and can allow for the isolation of particular metabolite subsets for analysis. GC-MS can provide relatively precise quantification of metabolites, as well as chemical structural information that can be compared to pre-existing chemical libraries. GC-MS can be conducted in a relatively high-throughput manner (greater than 100 samples per day) with greater detection sensitivity than NMR analysis. A limitation of GC-MS for this application, however, is that processed metabolite components must be readily volatilized for sample processing. LC-MS initially separates out the components of a sample mixture based on properties such as hydrophobicity, before processing them for identification and quantification by mass spectrometry (MS). Overall, LC-MS is an extremely flexible method for processing most compound types in a somewhat high-throughput manner (20-100 samples a day), also with greater sensitivity than NMR analysis. For both GC-MS and LC-MS there are limitations in the reproducibility of metabolite quantification.
Genetic predisposition to substance use and a history of substance use increase the risk of persistent discontinuation syndrome symptoms. Treatment for physical withdrawal generally involves switching the patient to a long-acting benzodiazepine such as diazepam or clonazepam, then slowly titrating them off the replacement drug completely at a rate that is both reasonably comfortable for the patient but rapid enough for the managing physician to consider the rate of progress acceptable (overly rapid dose reduction greatly increases the risk of patient non-compliance, such as the use of illicitly obtained alternative sedatives and/or alcohol). Psychotherapy and cognitive behavioral therapy have demonstrated moderate success in reducing the rebound anxiety that results upon carisoprodol discontinuation but only when combined with regular and active attendance to a substance use support group. Carisoprodol withdrawal can be life-threatening (especially in high-dose users and those who attempt to quit "cold turkey"). Medical supervision is recommended, with gradual reduction of dose or a substitute medication, as with other depressant drugs.
Fractyl Health is a Burlington, Massachusetts-based healthcare company focused on metabolic diseases like obesity and type 2 diabetes. The company developed Revita, an outpatient endoscopic procedure to modify duodenal dysfunction, and Rejuva, a gene therapy platform in preclinical development to enable the pancreas to produce glucagon-like peptide-1 (GLP-1).
Sources: en.wikipedia.org
== Economics and finance == Repurchase agreement, the sale of securities together with an agreement for the seller to buy back the securities at a later date Reservation price, the highest price a buyer is willing to pay for goods or a service Rupee, common name for the currencies of several countries Rupiah, the official currency of Indonesia
== Factor XIII deficiency == Factor XIII deficiency, while generally rare, does occur, with Iran having the highest global incidence of the disorder with 473 cases. The city of Khash, located in Sistan and Balochistan provinces, has the highest incidence in Iran, with a high rate of consanguineous marriage.
== External links == Archer J.P. Martin on Nobelprize.org Portraits of Archer Martin at the National Portrait Gallery, London Martin's Nobel lecture: The Development of Partition Chromatography M Martin's Column's: Classic Kit
This article was submitted to WikiJournal of Medicine for external academic peer review in 2021 (reviewer reports). The updated content was reintegrated into the Wikipedia page under a CC-BY-SA-3.0 license (2021). The version of record as reviewed is: Kholhring Lalchhandama; et al. (2021). "History of penicillin" (PDF). WikiJournal of Medicine. 8 (1): 3. doi:10.15347/wjm/2021.003. Wikidata Q107303937.
A proton is a stable subatomic particle, symbol p, H+, or 1H+ with a positive electric charge of +1 e (elementary charge). Its mass is slightly less than the mass of a neutron and approximately 1836 times the mass of an electron (the proton-to-electron mass ratio). Protons and neutrons, each with a mass of approximately one dalton, are jointly referred to as nucleons (particles present in atomic nuclei). One or more protons are present in the nucleus of every atom. They provide the attractive electrostatic central force which binds the atomic electrons. The number of protons in the nucleus is the defining property of an element, and is referred to as the atomic number (represented by the symbol Z). Since each element is identified by the number of protons in its nucleus, each element has its own atomic number, which determines the number of atomic electrons and consequently the identity and chemical characteristics of the element. The word proton is Greek for "first", and the name was given to the hydrogen nucleus by Ernest Rutherford in 1920. In previous years, Rutherford had discovered that the hydrogen nucleus (known to be the lightest nucleus) could be extracted from the nuclei of nitrogen by atomic collisions. Protons were therefore a candidate to be a fundamental or elementary particle, and hence a building block of nitrogen and all other heavier atomic nuclei.
Sources: en.wikipedia.org
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.
In animal studies it showed greater selectivity for growth hormone release, with less effect on cortisol and adrenocorticotropic hormone than compounds such as GHRP-6. This selectivity is one of the most frequently cited features in preclinical literature. Whether the same profile applies in other contexts is not fully established.
The receptor-level events are reasonably well described, but the full range of downstream effects is not. Studies have reported activity in tissues beyond the pituitary, including the gut. How these observations translate across species and conditions remains an open question.
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.